TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11280194
Drug: Oka-derived varicella
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain Injection [Varivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oka-derived varicella vaccines administered post-exposure within 3 days of rash onset
Study: 9272811
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg p.o.)
Study: 9272811
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg/day) with Morphine
Study: 26580307
Drug: Light monotherapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light monotherapy (10,000-lux fluorescent white light box for 30 min/d in the early morning plus placebo pill)
Study: 26580307
Drug: Fluoxetine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine monotherapy (inactive negative ion generator for 30 min/d plus fluoxetine hydrochloride, 20 mg/d)
Study: 26580307
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (light and antidepressant)
Study: 26580307
Drug: Placebo (inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive negative ion generator plus placebo pill)
Study: 26342028
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg) daily for 14 days
Study: 26342028
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg)/isoniazid (300 mg) daily for 14 days
Study: 26342028
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg)/isoniazid (300 mg) after washout
Study: 26342028
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg) after washout
Study: 20683270
Drug: EVG/COBI 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVG/COBI 150 mg/FTC/TDF
Study: 16786387
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same osteoporosis drug therapy)
Study: 16786387
Drug: New traumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New traumatic vertebral body fractures (managed by fixateur interne alone or combination with kyphoplasty)
Study: 11998139
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy methods for urinary incontinence
Study: 1524963
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage of pyridostigmine (30 mg three times daily)
Study: 1524963
Drug: Transdermal hyoscine
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal hyoscine patches
Study: 3890160
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with hip joint distension arthrography
Study: 20185416
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus 10 sessions of biofeedback-assisted relaxation training (BART)
Study: 20185416
Drug: Standardized medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized medication treatment
Study: 17919380
Drug: HTEA (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTEA (high thoracic epidural anesthesia) with 0.5% lidocaine 3 ‐ 5 ml every two hours for one month
Study: 17919380
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine medication)
Study: 12173196
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg orally every 8 h the day before surgery and 75 mg i.m. every 12 h on the day of surgery)
Study: 9443711
Drug: Tiagabine 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 32 mg daily
Study: 9443711
Drug: Tiagabine 56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 56 mg daily
Study: 9443711
Drug: Tiagabine 16
Normalized name: tiaGABine 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 16 mg daily
Study: 2379255
Drug: Simultaneous inoculation
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous inoculation with DPT and BCG vaccines
Study: 30820923
Drug: Solution based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution based on autonomy
Study: 30820923
Drug: Solution based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution based on coercion
Study: 30820923
Drug: Solution based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution based on reciprocity
Study: 23796582
Drug: Fidaxomicin 200
Normalized name: fidaxomicin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidaxomicin 200 mg b.i.d. for 10 days
Study: 23796582
Drug: Vancomycin 125
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 125 mg q.i.d. for 10 days
Study: 21835296
Drug: Combination antihypertensive
Normalized name: ANTIHYPERTENSIVE COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antihypertensive therapy (thiazide and potassium-sparing diuretic; thiazide and angiotensin-converting enzyme inhibitor)
Study: 21835296
Drug: Single-drug initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-drug initial therapy
Study: 19843489
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of valsartan 160 mg
Study: 19843489
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of valsartan 160 mg
Study: 15212193
Drug: Drotaverine capsule
Normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotaverine capsule preparation (20 mg Droxa mite)
Study: 15212193
Drug: Reference tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference tablet preparation
Study: 9059680
Drug: Cyclosporine at
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine at 3 mg/kg/day
Study: 9059680
Drug: Topical betamethasone-17,21-dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone-17,21-dipropionate
Study: 3527592
Drug: Oral 1
Normalized name: SYRINGE,ORAL 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 1 g Neomycin plus 0.25 g Metronidazole t.i.d. on the last preoperative day
Study: 3527592
Drug: Intravenous single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous single dose 5 g Mezlocillin plus 0.5 g Metronidazole
Study: 28830491
Drug: BioLex®-GLM (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioLex®-GLM (600 mg daily)
Study: 16564374
Drug: Multilevel surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multilevel surgical protocol including uvulaflap, tonsillectomy, hyoid suspension, and radiofrequency treatment of the tongue base (group A)
Study: 16564374
Drug: Surgery without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery without hyoid suspension (group B)
Study: 9357885
Drug: Dexmedetomidine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine at concentrations of 0.3 ng/ml and 0.6 ng/ml
Study: 8096945
Drug: Leukotriene LTE4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene LTE4 inhalation
Study: 3803701
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate spray (2.5 mg, 2 squirts, administered 2 min before testing)
Study: 29571817
Drug: mOPV2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: mOPV2 doses at 1 week interval (n=191)
Study: 29571817
Drug: mOPV2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: mOPV2 doses at 2 weeks interval (n=191)
Study: 29571817
Drug: mOPV2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: mOPV2 doses at 4 weeks interval (n=188)
Study: 29571817
Drug: mOPV2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: mOPV2 doses at 4 weeks interval plus IPV (n=190)
Study: 16626384
Drug: Skin-lightening gel
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Skin-lightening gel with ultrasound
Study: 16626384
Drug: Skin-lightening gel
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Skin-lightening gel treatment
Study: 10024108
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil emulsion + 1.8 g/day EPA
Study: 2279535
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PGI2 and PGE1
Study: 2279535
Drug: Second infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second infusion of the same compound
Study: 25131348
Drug: Higher fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher fiber intake (8.3 g/day increase)
Study: 17270513
Drug: Twice-weekly supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly supervised pulmonary rehabilitation (2 sessions/week)
Study: 17270513
Drug: Once-weekly supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly supervised pulmonary rehabilitation (1 session/week)
Study: 12174159
Drug: Methenamine hippurate
Normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine hippurate (1 g Hiprex, twice daily for 5 days)
Study: 9869506
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg, t.d.s.)
Study: 9869506
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 mg, o.d.)
Study: 7989628
Drug: 5 percent
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 percent EMLA cream
Study: 7989628
Drug: 5 percent
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 percent lidocaine ointment
Study: 25697763
Drug: Cryo-ultrasound (cryo-US)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryo-ultrasound (cryo-US) therapy
Study: 23427839
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment using manualized hypnosis
Study: 23427839
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment using manualized hypnosis
Study: 16834789
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (50 mg kg‐1 in 100 mL of isotonic saline over 20 min)
Study: 9305483
Drug: Oral elemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral elemental diet (Peptamen, Clintec, USA) for 2 weeks
Study: 2572741
Drug: Oleic acid
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oleic acid (3.5 g)
Study: 2572741
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (30 g, predominantly diunsaturated)
Study: 2572741
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (30 g, predominantly monounsaturated)
Study: 2572741
Drug: Suet (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suet (30 g, predominantly saturated)
Study: 30711603
Drug: Conventional method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional method (C) - custom tray with impression compound and silicone
Study: 28551715
Drug: Methylphenidate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (60 mg)
Study: 12433007
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise and medication
Study: 30718126
Drug: Interval cytoreductive
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval cytoreductive surgery (ICS) + hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 23257667
Drug: Bright Futures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright Futures Oral Health curriculum
Study: 19351801
Drug: Caffeine plus
Normalized name: Caffeine Plus Green Tea Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine plus zolpidem (10 mg)
Study: 19351801
Drug: Caffeine plus
Normalized name: Caffeine Plus Green Tea Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine plus trazodone (100 mg)
Study: 15229817
Drug: Aprotinin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (1 Mio KIE) administered at the latest 15 min before delivery
Study: 2952619
Drug: Vasopressin derivative
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin derivative (daily for 10 days)
Study: 2952619
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of vasopressin derivative
Study: 2952619
Drug: Vasopressin treatment
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin treatment (three times weekly for 6 weeks in rats)
Study: 8649563
Drug: rIFNbeta (unspecified
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFNbeta (unspecified dose)
Study: 31401049
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine (7 mg kg‐1) and IV midazolam (0.25 mg kg‐1)
Study: 31401049
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole (5 mg kg‐1) administered 12 and 24 hours prior to ketamine-midazolam
Study: 22337532
Drug: VDW chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VDW chemotherapy data for trastuzumab
Study: 22337532
Drug: VDW chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VDW chemotherapy data for anthracyclines
Study: 22337532
Drug: VDW chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VDW chemotherapy data for other chemotherapy
Study: 22337532
Drug: VDW mean
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: VDW mean doses for trastuzumab
Study: 22337532
Drug: VDW mean
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: VDW mean doses for anthracyclines
Study: 19818174
Drug: Coartem Dispersible
Normalized name: Coartem
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coartem Dispersible (dispersible formulation of artemether/lumefantrine)
Study: 19818174
Drug: Crushed AL
Normalized name: AL-034
DrugBank: AL-034 (DB17471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed AL tablets (control)
Study: 9750527
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy for 2 years
Study: 9750527
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy for 2 years (stage C cancer)
Study: 7825970
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of 5FU
Study: 3339175
Drug: Superior vena
Normalized name: Sus scrofa superior gastric plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superior vena cava spring-left ventricular patch electrode system (6.7 cm2 anode, 13.5 cm2 cathode)
Study: 3339175
Drug: Spring-patch system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spring-patch system
Study: 20203627
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day of flavanol-rich dark chocolate
Study: 20203627
Drug: 25 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g/day of flavanol-rich dark chocolate
Study: 10326149
Drug: New thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New thrombolytic agents (including reteplase, TNK-t-PA, lanoteplase)
Study: 10326149
Drug: Thrombolytics combined
Normalized name: THROMBOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytics combined with new glycoprotein IIb/IIIa platelet inhibitors and anti-thrombin agents
Study: 1725033
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg/day (treatment A)
Study: 1725033
Drug: Ramipril 1.25
Normalized name: ramipril 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 1.25 mg/day (treatment B)
Study: 6940466
Drug: High-dose induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose induction chemotherapy (TAD) consisting of 6-thioguanine, cytarabine, and daunorubicin
Study: 6940466
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation chemotherapy followed by maintenance chemotherapy with immunotherapy
Study: 6940466
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation chemotherapy followed by maintenance chemotherapy without immunotherapy
Study: 31775859
Drug: Intravaginal lactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal lactic acid gel 5 ml once daily for 7 days
Study: 31775859
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole tablets 400 mg twice daily for 7 days
Study: 23246229
Drug: Berberine gelatin
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine gelatin (5 mg/g) applied 4 times per day for 5 days
Study: 21413865
Drug: Micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplement containing 12 vitamins and 9 minerals
Study: 19684155
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) treatment for 12 months
Study: 19684155
Drug: Etanercept treatment
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept treatment for nonresponders after 12 months of MTX
Study: 15980646
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol termination
Study: 15980646
Drug: Intra-amniotic injection
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic injection of prostaglandin termination
Study: 6633618
Drug: Single-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose therapy with trimethoprim/sulfamethoxazole (43 courses)
Study: 6633618
Drug: Single-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose therapy with tobramycin (23 courses)
Study: 6633618
Drug: Therapy to
Normalized name: COOL THERAPY Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy to eradicate bacteriuria
Study: 29952801
Drug: HeartMate II
Approvals — FDA: no, EMA: no, PMDA: no
Description: HeartMate II pump position at implant
Study: 28145818
Drug: Health education,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education, diet supervision and exercise supervision (twice a week)
Study: 26054185
Drug: Dentifrices containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrices containing 1.5% arginine, 1450 ppm fluoride as sodium monofluorophosphate (MFP), and an insoluble calcium compound (either dicalcium phosphate or calcium carbonate)
Study: 23686738
Drug: Monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly ibandronate (150 mg)
Study: 23686738
Drug: Weekly alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly alendronate (70 mg)
Study: 17803060
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (10 mg amlodipine tablet - Intervask)
Study: 17803060
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug vs Reference drug
Study: 10483844
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy (CBT) with instructions to drop safety behaviours
Study: 10483844
Drug: Standard cognitive-behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive-behaviour therapy (CBT)
Study: 8630576
Drug: FK‐888 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK‐888 (2.5 mg)
Study: 7049959
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (75 mg/kg body weight)
Study: 30707660
Drug: GEMOX (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOX (gemcitabine 1,000 mg/m2 on day 1 and oxaliplatin 85 mg/m2 on day 2 of a 2-week cycle for 12 cycles)
Study: 12413183
Drug: Interviewer-administered questionnaires
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered questionnaires (IAQ)
Study: 9857596
Drug: 35% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% phosphoric etching gel (pH 1) applied in the peri-implant sulcus
Study: 9857596
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy with supra- and subgingival debridement using carbon fiber curettes and a rubber cup
Study: 8730504
Drug: Combined low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined low antigen diet and therapy
Study: 26575180
Drug: Bupivacaine lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine lozenge